| Title | Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. |
| Publication Type | Journal Article |
| Year of Publication | 2012 |
| Authors | Pol, Stanislas, Reem H. Ghalib, Vinod K. Rustgi, Claudia Martorell, Greg T. Everson, Harvey A. Tatum, Christophe Hézode, Joseph K. Lim, Jean-Pierre Bronowicki, Gary A. Abrams, Norbert Bräu, David W. Morris, Paul J. Thuluvath, Robert W. Reindollar, Philip D. Yin, Ulysses Diva, Robert Hindes, Fiona McPhee, Dennis Hernandez, Megan Wind-Rotolo, Eric A. Hughes, and Steven Schnittman |
| Journal | The Lancet infectious diseases |
| Volume | 12 |
| Issue | 9 |
| Pagination | 671-7 |
| Date Published | 2012 Sep |
| ISSN | 1474-4457 |
| Keywords | Adult, Aged, Antiviral Agents, Double-Blind Method, Drug Therapy, Combination, Female, France, Genotype, Hepacivirus, Hepatitis C, Chronic, Humans, Imidazoles, Interferon-alpha, Male, Middle Aged, Placebos, Polyethylene Glycols, Recombinant Proteins, Ribavirin, RNA, Viral, Treatment Outcome, United States, Viral Load |
| Abstract | Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and dosing schedules. Once-daily daclatasvir, a potent NS5A replication complex inhibitor, was generally well tolerated in phase 1 studies. We assessed daclatasvir in combination with pegylated interferon (peginterferon) and ribavirin for chronic HCV. |
| DOI | 10.1353/hpu.2012.0006 |
| Alternate Journal | Lancet Infect Dis |
